2026-10-14T01:46:46Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34009200 2026-09-28T05:36:11Z category_15 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Evaluation of peripheral and intranigral AAV-mediated Irisin delivery in a chronic AAV-A53T α-Synuclein overexpression mouse model of Parkinson’s disease.docx Chunyan Shu (20999738) Jiehong Huang (23961144) Wandi Pu (25119807) Haoyuan Liang (25119810) Zucai Xu (9227159) Xijin Wang (5337419) Lixi Li (3170661) Neuroscience AAV9-A53T Irisin neuroprotection Parkinson’s disease α-Synuclein Background<p>Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra and pathological aggregation of α-Synuclein (α-Syn). Although Irisin has shown neuroprotective effects in acute MPTP-induced and α-Syn preformed fibrils (PFFs) propagation models, its therapeutic effects in a chronic α-Syn overexpression model remain incompletely defined.</p>Methods<p>In the present study, we evaluated the effects of AAV8-Irisin delivered either peripherally via tail vein injection or centrally via direct intranigral co-administration in the AAV9-A53T mouse model.</p>Results<p>Under the tested doses, routes, and intervention schedule, neither peripheral nor intranigral AAV8-Irisin delivery produced statistically significant improvements in behavioral performance, dopaminergic neuron survival, α-Synuclein pathology, glial activation, or AQP4 polarization; however, numerical trends were observed in select measures, including motor coordination and TH-positive neuron counts.</p>Conclusion<p>These findings suggest that, under the current experimental conditions, a clear neuroprotective benefit of Irisin was not readily detectable in this model. Whether modest effects might emerge under different exposure levels, intervention windows, or adequately powered designs remains unknown.</p> 2026-09-28T05:36:11Z Dataset Dataset 10.3389/fnagi.2026.1918326.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Evaluation_of_peripheral_and_intranigral_AAV-mediated_Irisin_delivery_in_a_chronic_AAV-A53T_-Synuclein_overexpression_mouse_model_of_Parkinson_s_disease_docx/34009200 CC BY 4.0